- Researchers say they can predict more severe kidney and cardiovascular disease in people with type 2 diabetes when biomarker values are assessed at baseline, after one year, and at three years.
- The biomarkers were used to measure the effects of the drug canagliflozin on disease severity.
- The researchers said the study results strengthen previous data showing a high incident rate of cardiovascular disease in people with type 2 diabetes
A blood test could help predict the risk of progressive heart and kidney disease in people with type 2 diabetes and kidney disease, according to
In their study, researchers
The scientists checked the biomarkers at the start of the study, the one-year mark, and the three-year mark.
The scientists also looked at the predictive value of the biomarkers on various levels of kidney problems and the risk of death due to kidney disease or cardiovascular disease.
The researchers looked for biomarker values above those seen in healthy individuals, which would predict cardiovascular and renal events. Based on the levels of the biomarkers, the researchers divided participants into low, medium, and high-risk categories.
The scientists reported that people with the highest risk showed higher rates of progressive kidney failure and cardiovascular complications throughout the three-year follow-up period.
Results of the study included:
- High concentrations of the biomarkers at the beginning of the study predicted the severity of the participants’ heart and kidney issues.
- The biomarkers in those taking canagliflozin were lower after one year and three years as compared to those taking a placebo.
- After one year, all…
Read the full article here